1 Title: The NR5A1/SF-1 variant p.Gly146Ala cannot explain the phenotype of individuals with a

2 difference of sex development.

3

Idoia Martinez de Lapiscina^{1,2,3,4,5,6}, Chrysanthi Kouri^{1,2,7}, Josu Aurrekoetxea^{8,9}, Mirian Sanchez³, Rawda 4 Naamneh Elzenaty^{1,2,7}, Kay-Sara Sauter^{1,2}, Núria Camats^{5,10}, Gema Grau^{3,6,11}, Itxaso Rica^{3,4,5,6,11}, Amaia 5 Rodriguez^{3,11}, Amaia Vela^{3,4,5,6,11}, Alicia Cortazar^{4,12}, M. Concepción Alonso-Cerezo¹³, Pilar Bahillo¹⁴, 6 Laura Berthod¹⁵, Isabel Esteva¹⁶, Luis Castaño^{3,4,5,6,9,11,*}, Christa E. Flück^{1,2,*} 7

8

9 ¹Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. ²Department for BioMedical Research, 10 University of Bern, Bern, Switzerland. ³Research into the genetics and control of diabetes and other 11 12 endocrine disorders, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain. ⁴CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto 13 14 de Salud Carlos III, Madrid, Spain. ⁵CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain. ⁶Endo-ERN, Amsterdam, The Netherlands. ⁷Graduate School for Cellular and 15 Biomedical Sciences, University of Bern, Bern, Switzerland. ⁸Research group of Medical Oncology, 16 17 Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain. ⁹University of the Basque Country (UPV-EHU), Leioa, Spain. ¹⁰Growth and Development group, Vall d'Hebron 18 Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain. ¹¹Department of 19 20 Pediatric Endocrinology, Cruces University Hospital, Barakaldo Spain. ¹²Endocrinology Department, Cruces University Hospital, Barakaldo, Spain. ¹³La Princesa University Hospital, Madrid, Spain. 21 22 ¹⁴Pediatric Endocrinology Unit, Department of Pediatrics, Clinic University Hospital of Valladolid, Valladolid, Spain. ¹⁵Pediatric Endocrinology Department, Margues de Valdecilla University Hospital, 23 24 Santander, Spain. ¹⁶Endocrinology Section, Gender Identity Unit, Regional University Hospital of 25 Malaga, Malaga, Spain.

26 *Co-last authors

27

28 Corresponding author: Idoia Martinez de Lapiscina, PhD; idoia.martinezdelapiscina@unibe.ch

- 29 Phone Nr: +41316641475
- 30

31 Short title: Role of NR5A1/SF-1 p.Gly146Ala in DSD

- 32
- 33

34 Abstract

Steroidogenic factor 1 (SF-1, NR5A1) plays an important role in human sex development. Variants of 35 36 NR5A1/SF-1 may cause mild to severe differences of sex development (DSD) or may be found in 37 healthy carriers. So far, the broad DSD phenotypic variability associated NR5A1/SF-1 variants remains 38 a conundrum. The NR5A1/SF-1 variant c.437G>C/p.Gly146Ala is common in individuals with a DSD and 39 has been suggested to act as a susceptibility factor for adrenal disease or cryptorchidism. However, as 40 the allele frequency in the general population is high, and as functional testing of the p.Gly146Ala 41 variant in vitro revealed inconclusive results, the disease-causing effect of this variant has been 42 questioned. However, a role as a disease modifier in concert with other gene variants is still possible 43 given that oligogenic inheritance has been described in patients with NR5A1/SF-1 gene variants. Therefore, we performed next generation sequencing in DSD individuals harboring the NR5A1/SF-1 44 45 p.Gly146Ala variant to search for other DSD-causing variants. Aim was to clarify the function of this variant for the phenotype of the carriers. We studied 14 pediatric DSD individuals who carried the 46 47 p.Gly146Ala variant. Panel and whole-exome sequencing was performed, and data were analyzed with a specific data filtering algorithm for detecting variants in NR5A1- and DSD-related genes. The 48 49 phenotype of the studied individuals ranged from scrotal hypospadias and ambiguous genitalia in 50 46,XY DSD to typical male external genitalia and ovotestes in 46,XX DSD patients. Patients were of 51 African, Spanish, and Asian origin. Of the 14 studied subjects, five were homozygous and nine 52 heterozygous for the NR5A1/SF-1 p.Gly146Ala variant. In ten subjects we identified either a clearly 53 pathogenic DSD gene variant (e.g. in AR, LHCGR) or one to four potentially deleterious variants that 54 likely explain the observed phenotype alone (e.g. in FGFR3, CHD7, ADAMTS16). Our study shows that 55 most individuals carrying the NR5A1/SF-1 p.Gly146Ala variant, harbor at least one other deleterious 56 gene variant which can explain the DSD phenotype. This finding confirms that the p.Gly146Ala variant 57 of NR5A1/SF-1 may not contribute to the pathogenesis of DSD and qualifies as a benign polymorphism. 58 Thus, individuals, in whom the NR5A1/SF-1 p.Gly146Ala gene variant has been identified as the 59 underlying genetic cause for their DSD in the past, should be re-evaluated with a next-generation 60 sequencing method to reveal the real genetic diagnosis.

61

62 Introduction

Typical sex development depends on the specific interactions of many genes and pathways in a 63 defined spatiotemporal sequence. Any perturbation in this very complex biological event, which 64 involves genetic and hormonal processes, may result in atypical sex development and leads to a broad 65 66 range of differences of sex development (DSD) in humans, also known as variations of sex 67 characteristics (VSC) (1). The NR5A1 gene, which encodes the steroidogenic factor 1 (SF-1), regulates multiple genes implicated in adrenal development, gonadal determination and differentiation, 68 69 steroidogenesis, and reproduction (2). Since the identification of the first NR5A1/SF-1 variation in a 70 46,XY patient with primary adrenal failure and complete gonadal dysgenesis (3), the gonadal and 71 reproductive phenotype associated with NR5A1/SF-1 variants has broadened including 46,XY and 72 46,XX cases with sex reversal to minor untypicalities such as hypospadias or even healthy carriers, 73 whereas adrenal failure has only been found in very rare cases (4, 5).

74 Currently, 291 different NR5A1/SF-1 variants are reported in the Human Gene Mutation Database 75 (HGMD, October 2022). Variants include missense/nonsense, indels, small insertions/deletions, 76 complete gene deletions or splice-site variants that are scattered throughout the whole gene without 77 obvious hot spots. According to ACMG (American College of Medical Genetics and Genomics) 78 classification (6), described variants may qualify as (likely) pathogenic or (likely) benign, and several 79 are variants of unknown significance (VUS).

80 The nonsynonymous *NR5A1*/SF-1 c.437G>C/p.Gly146Ala (rs1110061) variant has been first described 81 in a group of Japanese patients presenting with a series of adrenal diseases such as Cushing's 82 syndrome or non-functioning adrenocortical adenoma (7). In this context, WuQiang et al. reported 83 that the p.Gly146Ala variant slightly impairs the transactivation ability of adrenal and ovary specific 84 gene promoters but does not affect cofactor interaction and cellular localization (7). Later, it has been proposed to act as a susceptibility factor for cryptorchidism (8), isolated micropenis (9, 10), 85 86 spermatogenic failure (11, 12), primary ovarian insufficiency (POI) (13) and type 2 diabetes (14). The p.Gly146Ala variant is common among individuals with a 46,XY DSD with a prevalence varying 87 88 between 6.8 and 31% (15, 16). However, the minor allele frequency (MAF) (C allele) is also high in the 89 overall control population (23.5%, gnomAD v3.1.2). Specifically, its MAF is increased approximately by 90 1.3-3-fold in the East Asian and the African control populations, whereas it is only present in 1% of the European control population (gnomAD v3.1.2). Moreover, in vitro studies of transcriptional activity of 91 92 the NR5A1/SF-1 p.Gly146Ala variant on several target promoters in various cell models found unaltered wild-type functionality (15, 17). In fact, some patients who carry severe, pathogenic 93 94 NR5A1/SF-1 variants in compound heterozygous state with the p.Gly146Ala variant, do not 95 phenotypically differ from individuals carrying the severe variant only (5, 16-22). The DSD causing

96 effect of the *NR5A1*/SF-1 p.Gly146Ala variant is therefore in doubt. However, given that oligogenic 97 inheritance has been suggested for explaining the broad phenotype observed in individuals and 98 families with *NR5A1*/SF-1 gene variants (23-29), the p.Gly146Ala variant might play a role as co-99 regulator or disease modifier of sexual development.

The aim of this study was therefore, to elucidate the role of the *NR5A1/*SF-1 p.Gly146Ala variant on sexual development. We studied 14 DSD patients carrying this variant by next generation sequencing (NGS). Specifically, we searched for other DSD-causing variants and their pathogenicity in order to

- assess the effect of the *NR5A1/*SF-1 p.Gly146Ala variant on the phenotype of its carriers.
- 104

105 Patients and Methods

106 Patients and ethical approval

We recruited 14 pediatric DSD individuals carrying the *NR5A1/SF-1* p.Gly146Ala variant from a larger cohort of 125 DSD patients collected at the Biocruces Bizkaia Health Research Institute (Barakaldo, Spain). Clinical data were provided by the caring clinicians (Table 1 and S2 table). The study was approved by the ethics committee for clinical research of Euskadi (CEIC-E), Spain. Written informed consent was provided by the parents of the studied children.

- 112 Ten 46,XY DSD and four 46,XX DSD patients carrying the p.Gly146Ala variant in the *NR5A1*/SF-1 gene
- 113 were analyzed using whole exome sequencing (WES) or a targeted gene panel comprised of 48 genes
- associated with sex determination, sex differentiation and hypogonadism (Supplementary table 1).
- 115

116 Genetic analysis

Genomic DNA from the patients was extracted from peripheral blood leukocytes using the MagPurix
12S system (Zinexts Life Science Corp.). DNA purity and concentration were determined using a Qubit
2.0 fluorometer (Thermo Fisher Scientific).

120 Initial characterization for the NR5A1/SF-1 p.Gly146Ala variant was done by a DSD specific panel. 121 Additional NGS was performed by WES (Figure 1A). For WES, libraries were prepared using the Illumina 122 DNA/RNA Prep Tagmentation PCR reagents (Illumina) and Illumina Exome Panel (CEX) according to 123 the manufacturer's instructions. The resulting libraries were subjected to paired-end sequencing on a 124 NovaSeg 6000 System (Illumina). Raw data were then converted to FastQ files for computational analysis, which included read alignment to the human genome reference sequence (GRCh38), 125 duplicate marking, base quality score recalibration, indel realignment, and variant calling with an in-126 127 house bioinformatics pipeline using BWA-MEM (30) and GATK (31) software. Variants were annotated 128 with wANNOVAR (32) and filtration process of the exonic variants was performed using R software (R 129 4.2.0). Variant filtration was performed following specific steps as given in Figure 1B.

130 These steps included the filtration of WES data by a DSD- and *NR5A1*-related gene list. These disease-131 tailored lists were updated from previously reported work (DSD-gene list, N=584; NR5A1-related gene 132 list, N=628) (22, 32) (Figure 1 Step a). Then, we kept the resulting variants with all type of predicted 133 consequences (e.g. nonsynonymous, frameshift deletion, stop/gain), but synonymous, and with a 134 number of reads above or equal to 20 (33) (Figure 1 steps b and c). Next, we filtered to include variants 135 with a MAF ≤ 0.01 according to gnomAD (v3.1.2) and depending on the origin and karyotype of the patient (Figure 1 step d). In step e, we confirmed the correct annotation, location of variants and 136 137 zygosity by checking their alignment data in IGV (Integrative Genomics Viewer). Finally, we predicted 138 the possible effect of the identified variant (see below) (Figure 1 step f). Variants were confirmed by 139 visual examination using the IGV (Integrative Genomics Viewer) browser (34, 35).

For the targeted DSD-gene panel analysis, preparation of the libraries and sequencing have been
described elsewhere (24). For variant filtration after panel analysis, same steps b to f were followed
(Figure 1B).

143

144 In silico analyses and variant classification

145 We predicted the possible effect of identified nonsynonymous genetic variants on the structure and 146 function of the protein using Polyphen-2, (Polymorphism Phenotyping v2), Panther (Protein ANalysis 147 THrough Evolutionary Relationships), SNPs and GO, CADD (Combined Annotation Dependent 148 Depletion) and the calibrated scores given by VarSome (36) for Revel (Rare Exome Variant Ensemble 149 Learner), SIFT (Scale-invariant feature transform), Provean (Protein Variation Effect Analyzer), 150 Mutation taster and M-CAP (Mendelian Clinically Applicable Pathogenicity) (see Supplementary table 151 3). Variants were classified for pathogenicity according to the standards and guidelines of the ACMG 152 (6) using VarSome. We considered variants as candidates when classified as pathogenic, likely pathogenic or as VUS by the ACMG criteria or when classified as pathogenic or VUS by at least 7 out 153 154 of 9 prediction programs. Previously reported clinical associations were searched in ClinVar and HGMD 155 databases. In addition, the literature (e.g. PubMed) was searched for evidence of relationship with 156 DSD, sex development and the specific clinical phenotype of each study subject. We explored the 157 possible disease-causing variants' combinations using ORVAL (Oligogenic Resource for Variant 158 AnaLysis) (37).

159

160 **Results and Discussion**

161 In a random cohort of 125 subjects with a DSD, we identified the *NR5A1*/SF-1 p.Gly146Ala variant in 162 14 individuals (11.2%). The prevalence in 46,XY DSD subjects was 10.1% (10/99), and was in line with 163 previously reported prevalence in this population (15, 16). Prevalence was higher in 46,XX DSD (4/24,

164 16.7%). Of the 14 studied subjects, five were homozygous and nine heterozygous for the NR5A1/SF-1 165 p.Gly146Ala variant. The phenotype of the individuals ranged from typical for karyotype to mild and severe atypical in 46,XY as well as opposite sex in both 46,XY and 46,XX (Figure 2). Patients were of 166 African (8/14), Spanish (4/14) and Asian (2/14) origin. A summary of the clinical and biochemical 167 168 characteristics of the patients is given in Table 1 and Supplementary table 2. An overview of the 169 identified genes of our study subjects that likely play a role for the DSD phenotype in a concerted way 170 is given in Figure 3. In this Figure 3 the identified variants are shown within the network of established 171 genes of sex determination and differentiation.

- NGS performed in DSD individuals harboring the p.Gly146Ala variant in *NR5A1*/SF-1 revealed several deleterious/candidate variants that potentially explain the phenotype of the patients. Overall, we identified either a known pathogenic DSD variant or one to four potentially deleterious/candidate variants in 10 out of the 14 DSD individuals analyzed. A detailed summary of identified variants in other DSD-related genes is shown in Table 2 (further details in Supplementary tables 3 and 4).
- 177 In three patients we detected variants in known DSD-causing genes with our targeted gene panel, e.g. LHCGR, WT1, and AR. In 11 patients WES was performed and variants were filtered by candidate gene 178 179 lists (Figure 1). Overall, the NGS analysis identified 63 variants categorized as (likely) pathogenic or 180 VUS in 57 different genes, however further review of evidence of correlation with DSD, sex 181 development and phenotype of each patient with literature reduced this number to 20 potentially 182 deleterious/candidate variants in 18 genes in 10 subjects. In nine 46,XY DSD individuals 1-4 variants 183 were found in a total of 16 genes, while one 46,XX DSD person revealed two variants in two different genes (Table 2). All variants, identified either by gene panel or WES, but one (e.g. LHCGR), were 184 185 detected in heterozygosis or hemizygosis. Details of the rejected variants are given in Supplementary 186 table 4.
- In patient 1 two frameshift deletions in genes FGFR3 (c.1633 1634del; p.Cys545Hisfs*17) and INSR 187 188 (c.660 661del; p.Pro220Hisfs*4) and a stop-gain variant in ADAMTS16 (c.1822 1823del; p.His608*) 189 were found and predicted to be likely pathogenic by the ACMG criteria. FGFR3 is essential for testicular 190 development in humans (38), while INSR and ADAMTS16 are needed in murine genitourinary 191 development and testicular differentiation, respectively (39, 40). Variants in ADAMTS16 have also 192 been reported in heterozygosis in two 46,XY females with complete gonadal dysgenesis and a 46,XY DSD patient with ambiguous genitalia (41). Testing for a digenic combination network with ORVAL 193 194 showed no variant interaction between ADAMTS16 and FGFR3.
- We detected four heterozygous missense variants in four genes in **patient 3**. These were *GLI2* (c.3528G>T; p.Gln1176His), *CDH7* (c.1623C>A; p.His541Gln), *MYO7A* (c.2882G>A; p.Gly961Asp) and *VDR* (c.176C>T; p.Thr59Ile). The variant in *GLI2* (c.3528G>T; p.Gln1176His) was rated as pathogenic by

198 most of the *in silico* prediction tools and variants in additional genes were rated as VUS when analyzing 199 according to pathogenicity guidelines. Variants in *GLI2* have been described in syndromic DSD patients 200 together with short stature, primary hypogonadism, heart and craniofacial anomalies and 46,XY 201 gonadal dysgenesis (42), as well as in 46,XY non-syndromic DSD manifesting with female external 202 genitalia or with ambiguous genitalia (23, 43, 44). Variants in CHD7 have been previously associated 203 with a broad range of 46,XY DSD phenotypes, including males with hypospadias or micropenis and 204 individuals with female external genitalia (27, 45). MYO7A is overexpressed in male supporting cells 205 during gonadal development (46) and has been shown to be a SRY and SOX9 target gene (47), but, in 206 DSD individuals it has been identified only in combination with MAMLD1 (44, 48). Finally, VDR plays a 207 dominant role in male fertility as Vdr^{-/-} mice show abnormal gonads in both sexes and variable reproductive phenotypes such as reduced sperm count (49). In humans, two polymorphisms in VDR 208 209 were associated with female idiopathic infertility only (50). Fertility of patient 3 has not been assessed 210 yet, and we cannot exclude a role of the VDR variant in his DSD phenotype. Network analysis by ORVAL 211 predicts a pathogenic gene network between CHD7, MYO7A and GLI2 (Supplementary figure 1A).

A heterozygous missense c.182C>A; p.Pro61Gln variant in Neuropilin 1 (NRP1) gene was found in 212 213 patient 6. NRP1 interacts with Sema3A which is essential for the development of the GnRH neuron 214 system (51). Loss of Sema3a (Semaphorin 3A) signaling in mice results in reduced gonadal size and 215 recapitulates the features of Kallmann syndrome (52). In humans, variants in NRP1 have been 216 identified in a 46,XY DSD subject with female external genitalia (45) and a 46,XY male presenting with 217 penoscrotal hypospadias, in whom other genetic variants were identified, among them a variant in MAMLD1, a known DSD-related gene (48). 218

219 In 46,XY patient 8 with a phenotype of opposite sex a homozygous, inactivating variant in LHCGR 220 (c.757T>C; p.Ser253Pro) was found. This variant has been previously reported to severely reduce the 221 signal transduction activity of the LH receptor and therefore leads to the complete form of Leydig cell 222 hypoplasia (LCH) as seen in patient 8 (53).

223 A novel, likely pathogenic p.Met255Lys (c.764T>A) missense variant in exon 2 of WT1 was found in 224 patient 9, who had precocious puberty and presented with a pituitary adenoma and hearing loss. WT1 225 is associated with 46,XY gonadal dysgenesis in syndromes including Denys-Drash or Frasier (54), but 226 more recently WT1 variants have also been detected in individuals with isolated DSD, such as ambiguous genitalia (45, 55, 56) or gonadal dysgenesis. WT1 acts as a transcriptional repressor or 227 228 activator on many target genes, such as LHB (Luteinizing Hormone Subunit Beta), which encodes the 229 beta subunit of LH (luteinizing hormone), responsible for testosterone production in males during 230 puberty. Variants of WT1 may therefore affect the transcription of LHβ and thereby lead to altered 231 puberty timing as observed in patient 9. In fact, in mouse cell models, WT1 regulates LHB transcription

and two splice variants (-KTS/+KTS) were already shown to have positive and negative roles in thisregulation (57).

234 A missense variant in COL27A1 (c.3715C>T; p.Arg1239Trp) and a frameshift insertion in TYRO3 (c.666 667insCACTGCCTGCAGCCCCTTCAACATCACC; p.Ala223HisfsTer21) were found in patient 10. 235 236 Both variants were categorized as VUS and were detected in heterozygosis. In mice, *Col27a1* is highly 237 expressed in XY somatic supporter cells compared to XX during the earliest stages of gonad 238 development (58). Col27a1 has been identified as a SRY target gene in the embryonic mouse gonads 239 at E11.5 by ChIP-Chip experiments (47). Similarly, Tyro3 is overexpressed in male somatic cells (59), 240 and is regulated by SOX9 (47). Protein truncating variants of TYRO3 were found in individuals with 241 idiopathic hypogonadotropic hypogonadism establishing a role of this gene in reproductive 242 development (60). Taken together, the data suggest that both COL27A1 and TYRO3 genes are part of 243 the genetic network underlying the early stages of mammalian fetal gonadal development, and thus 244 genetic changes are likely causing the ovotesticular DSD phenotype in patient 10. However, a gene 245 interaction between COL27A1 and TYRO3 was not predicted by ORVAL.

246 In 46,XY patient 11 with a distal hypospadias, one missense variant in the SOX8 (c.676A>C; 247 p.Thr226Pro) gene was detected. It was identified in heterozygosis and was classified as VUS. SOX8 is 248 involved in early testis determination (61). SOX8 gene variants are associated with a range of 249 phenotypes including 46,XY DSD and human reproductive anomalies in males and females (62). Single-250 nucleotide variants (SNV) associated with 46,XY gonadal dysgenesis are mostly located in the HMG-251 box of SOX8 (43), while those reported in infertile patients flank the HMG-box or localize to one of the 252 transactivation domains (TA) (62). However, more recently, a missense variant in the TA2 region of 253 SOX8 was identified in a 46,XY patient with gonadal dysgenesis (43). The novel c.676A>C; p.Thr226Pro 254 variant is located in the first TA of the protein. In vitro studies have shown impaired cellular localization 255 in some mutant proteins located in this functional domain of SOX8. Therefore, this missense variant 256 likely explains the genital phenotype observed in patient 11. Biochemical assessment (age range 11-257 15) of the HPG axis was normal and pubertal development was ongoing (Tanner 3-4).

258 Four heterozygous VUS or likely pathogenic variants were identified in **patient 12** with a severe 46,XY 259 DSD phenotype. These were POR (c.1679C>T; p.Thr560Met), PKD1 (c.2624C>T; p.Pro875Leu), SRCAP 260 (c.7142G>A; p.Arg2381His) and SOX9 (c.710dup; p.Pro238Thrfs*14). The involvement of POR and SOX9 in sexual development is well known and several sequence variants have been described in 46,XY 261 DSD patients (27, 47, 63). Pkd1 is critical for epididymal epithelium development and for maintaining 262 263 mice male reproductive tract (64). PKD1 variants have not been related to DSD yet, but they cause 264 autosomal dominant polycystic kidney disease (ADPKD), which involves reproductive tract 265 abnormalities and infertility in males (65). Therefore, a role of *PKD1* variants in DSD seems possible.

Likewise, the role of *SRCAP* in sex differentiation and development is unknown. However, this is the second 46,XY DSD patient in whom a gene variant is identified (42). According to ORVAL analysis, oligogenic pathogenicity is predicted by combination of variants in a gene network including *POR*, *PKD1* and *SRCAP* (Supplementary figure 1B).

In patient 13, we identified an *AR* variant (c.2323C>T; p.Arg775Cys) previously reported in a patient
with Complete Androgen Insensitivity Syndrome (CAIS) (66). Because the patient presented with a
typical CAIS phenotype, it seems plausible that this hemizygous *AR* variant is fully responsible for the
DSD.

- 274 Patient 14, with a severe 46,XY phenotype, harbored two heterozygous missense variants in MYO7A 275 and SOX8 genes. Both were categorized as VUS by the ACMG. As in patient 11, the SOX8 variant 276 (c.694A>C; p.Lys232Gln) was also located in the TA1 domain of the protein. However, the phenotype 277 of patient 14 was more severe, either caused by the SOX8 variant alone or due to the digenic effect 278 together with MYO7A. Importantly, the combination of variants in SOX8 and MYO7A is predicted as 279 disease-causing by ORVAL (Supplementary figure 1C). The combination of variants in MYO7A and SOX8 280 in DSD was reported previously (44, 48), and suggests that the broad phenotype observed in DSD 281 individuals might be explained by oligogenic origin (67).
- 282

283 In four patients carrying the heterozygous p.Gly146Ala NR5A1 variant, the WES and specific data 284 analysis revealed no other candidate genes explaining their DSD phenotype. Of these patients 2, 4 and 285 5 had a 46,XX karyotype and an opposite genital phenotype, and were assigned as males at birth, 286 whereas patient 7 presented with a severe 46,XY DSD. None had other organ anomalies. Although 287 NGS has facilitated the identification of the underlying genetic defects of DSD, about 50% of 288 individuals with a 46,XY DSD remain without a molecular diagnosis with currently used methods (27). 289 We used WES in our study, while other genetic studies also search for variants in noncoding, regulatory 290 or intronic regions by whole genome sequencing (WGS). But even when using WGS, a considerable 291 number of patients are reportedly unsolved (68). Thus, other factors such as environmental factors or 292 epigenetic regulators have been suggested playing a role (68, 69). In addition, oligogenic or even 293 polygenic inheritance might be considered for explaining the broad phenotypes seen in some 294 individuals with a DSD (23-29, 48, 67, 70-73). In early days of genetic workup of DSD, patients were 295 studied by candidate Sanger sequencing. In 46,XY DSD subjects typical candidates were the AR, 296 SRD5A2 and NR5A1/SF-1; and once a genetic variant was found, additional genes were not tested. 297 Thus, some DSD patients that have been tested by the candidate approach may not have a correct 298 diagnosis and need to be retested by NGS.

299 In conclusion, NGS genetic analysis of DSD individuals carrying the p.Gly146Ala variant of the 300 *NR5A1*/SF-1 gene revealed variants in other genes (likely) explaining their phenotype. These gene 301 variants were either found in established DSD genes, were previously described or novel, and were 302 (likely) disease-causing either in a monogenic or in a suggested oligogenic fashion. Although we were 303 not able to find causal genetic variants in four out of 14 DSD individuals carrying the NR5A1/SF-1 304 p.Gly146Ala, our study supports the claim that this NR5A1/SF-1 variant is a benign polymorphism that does not play a role in the pathogenesis of DSD. Therefore, we strongly recommend reanalyzing DSD 305 306 patients of whom phenotype has been thought to be explained by this variant in order to find the real 307 underlying genetic cause.

- 308
- Acknowledgement 309
- 310 The authors thank the patients and their families for participating in our research.
- 311

312 **Competing interests**

- The authors have declared that no competing interests exist. 313
- 314

315 Funding

316 This work has been supported by the University of the Basque Country (UPV-EHU) (Spain) (IT1739-22)

- 317 and by the Swiss National Science Foundation (320030-197725). IM is supported by a Postdoctoral
- Fellowship Grant from the Education Department of Basque Government (Spain). JA is supported by 318
- 319 ASONMEC (Asociacion de Oncologia Medica del Hospital de Cruces) (Spain).
- 320

321 Supporting information

- 322 S1 Table. Genes included in the customized DSD panel and their suggested role in DSD.
- 323 S2 Table. Complete description of the phenotype and biochemical data of the DSD patients harbouring
- 324 the NR5A1/SF-1 p.Gly146Ala variant.

325 S3 Table 3. Gene variant characterization: allele frequency and disease prediction by ACMG 326 classification and by different in silico programs

- 327 aSpecific allele frequency for the origin and karyotype of the patient. bCADD phred score >20 indicates
- that the variant is predicted to be the 1% most deleterious substitution that you can do to the human 328 329 genome.
- 330 S4 Table. List of rejected variants identified in the DSD patients harbouring the NR5A1/SF-1
- 331 p.Gly146Ala variant. Variants were discarded after filtering due to weak relation to DSD, zygosity or
- 332 absence of correspondence to the phenotype.

333 S1 Figure. Potential oligogenic interaction networks of DSD- and NR5A1-related genes identified in 334 specific DSD individuals harbouring the NR5A1/SF-1 p.Gly146Ala variant. Networks were identified for 335 patients 3, 12 and 14 respectively. To search for potential oligogenic disease networks, the Oligogenic 336 Resource for Variant AnaLysis (ORVAL, https://orval.ibsquare.be/) was used. Nodes represent genes and edges connect two genes only, if between them there is at least one candidate disease-causing 337 338 variant combination predicted by VarCoPP. The colour of the edge represents the pathogenicity score 339 for that pair of genes. This score is represented in a colour range from brown (higher pathogenicity 340 score) to yellow (lower pathogenicity score).

341

medRxiv preprint doi: https://doi.org/10.1101/2023.02.13.23285760; this version posted February 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

342 References

343 Eggers S, Ohnesorg T, Sinclair A. Genetic regulation of mammalian gonad development. 1. 344 Nature reviews Endocrinology. 2014;10(11):673-83. 345 Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, Gurakan B, et al. Gonadal 2. 346 determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic 347 factor-1, in a dose-dependent manner. The Journal of clinical endocrinology and metabolism. 348 2002;87(4):1829-33. 349 3. Achermann JC, Ito M, Ito M, Hindmarsh PC, Jameson JL. A mutation in the gene encoding 350 steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nature genetics. 1999;22(2):125-6. 351 Fabbri-Scallet H, de Sousa LM, Maciel-Guerra AT, Guerra-Júnior G, de Mello MP. Mutation 352 4. 353 update for the NR5A1 gene involved in DSD and infertility. Hum Mutat. 2020;41(1):58-68. 354 5. Domenice S, Machado AZ, Ferreira FM, Ferraz-de-Souza B, Lerario AM, Lin L, et al. Wide 355 spectrum of NR5A1-related phenotypes in 46,XY and 46,XX individuals. Birth defects research Part C, 356 Embryo today : reviews. 2016;108(4):309-20. 357 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for 6. 358 the interpretation of sequence variants: a joint consensus recommendation of the American College 359 of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in 360 medicine : official journal of the American College of Medical Genetics. 2015;17(5):405-24. 361 7. WuQiang F, Yanase T, Wei L, Oba K, Nomura M, Okabe T, et al. Functional characterization of 362 a new human Ad4BP/SF-1 variation, G146A. Biochem Biophys Res Commun. 2003;311(4):987-94. Wada Y, Okada M, Fukami M, Sasagawa I, Ogata T. Association of cryptorchidism with 363 8. Gly146Ala polymorphism in the gene for steroidogenic factor-1. Fertility and sterility. 364 2006;85(3):787-90. 365 366 Paris F, De Ferran K, Bhangoo A, Ten S, Lahlou N, Audran F, et al. Isolated 'idiopathic' 9. 367 micropenis: hidden genetic defects? Int J Androl. 2011;34(6 Pt 2):e518-25. 368 Wada Y, Okada M, Hasegawa T, Ogata T. Association of severe micropenis with Gly146Ala 10. 369 polymorphism in the gene for steroidogenic factor-1. Endocrine journal. 2005;52(4):445-8. 370 Bashamboo A, Ferraz-de-Souza B, Lourenço D, Lin L, Sebire NJ, Montjean D, et al. Human 11. 371 male infertility associated with mutations in NR5A1 encoding steroidogenic factor 1. Am J Hum 372 Genet. 2010;87(4):505-12. 373 Röpke A, Tewes AC, Gromoll J, Kliesch S, Wieacker P, Tüttelmann F. Comprehensive 12. 374 sequence analysis of the NR5A1 gene encoding steroidogenic factor 1 in a large group of infertile 375 males. European journal of human genetics : EJHG. 2013;21(9):1012-5. 376 13. Philibert P, Paris F, Lakhal B, Audran F, Gaspari L, Saâd A, et al. NR5A1 (SF-1) gene variants in 377 a group of 26 young women with XX primary ovarian insufficiency. Fertility and sterility. 378 2013;99(2):484-9. 379 14. Liu W, Liu M, Fan W, Nawata H, Yanase T. The Gly146Ala variation in human SF-1 gene: its 380 association with insulin resistance and type 2 diabetes in Chinese. Diabetes Res Clin Pract. 381 2006;73(3):322-8. 382 15. Camats N, Pandey AV, Fernández-Cancio M, Andaluz P, Janner M, Torán N, et al. Ten novel 383 mutations in the NR5A1 gene cause disordered sex development in 46,XY and ovarian insufficiency 384 in 46,XX individuals. The Journal of clinical endocrinology and metabolism. 2012;97(7):E1294-306. 385 Tantawy S, Mazen I, Soliman H, Anwar G, Atef A, El-Gammal M, et al. Analysis of the gene 16. 386 coding for steroidogenic factor 1 (SF1, NR5A1) in a cohort of 50 Egyptian patients with 46,XY disorders of sex development. European journal of endocrinology. 2014;170(5):759-67. 387 388 Reuter AL, Goji K, Bingham NC, Matsuo M, Parker KL. A novel mutation in the accessory 17. 389 DNA-binding domain of human steroidogenic factor 1 causes XY gonadal dysgenesis without adrenal 390 insufficiency. European journal of endocrinology. 2007;157(2):233-8.

All rights reserved. No reuse allowed without permission.

18. Köhler B, Lin L, Ferraz-de-Souza B, Wieacker P, Heidemann P, Schröder V, et al. Five novel
mutations in steroidogenic factor 1 (SF1, NR5A1) in 46,XY patients with severe underandrogenization
but without adrenal insufficiency. Hum Mutat. 2008;29(1):59-64.

Hasegawa T, Fukami M, Sato N, Katsumata N, Sasaki G, Fukutani K, et al. Testicular
 dysgenesis without adrenal insufficiency in a 46,XY patient with a heterozygous inactive mutation of
 steroidogenic factor-1. The Journal of clinical endocrinology and metabolism. 2004;89(12):5930-5.

Bertelloni S, Dati E, Baldinotti F, Toschi B, Marrocco G, Sessa MR, et al. NR5A1 gene
mutations: clinical, endocrine and genetic features in two girls with 46,XY disorder of sex
development. Hormone research in paediatrics. 2014;81(2):104-8.

Woo KH, Cheon B, Kim JH, Cho J, Kim GH, Yoo HW, et al. Novel Heterozygous Mutations of
NR5A1 and Their Functional Characteristics in Patients with 46,XY Disorders of Sex Development
without Adrenal Insufficiency. Hormone research in paediatrics. 2015;84(2):116-23.

Adamovic T, Chen Y, Thai HT, Zhang X, Markljung E, Zhao S, et al. The p.G146A and p.P125P
polymorphisms in the steroidogenic factor-1 (SF-1) gene do not affect the risk for hypospadias in
Caucasians. Sexual development : genetics, molecular biology, evolution, endocrinology,
embryology, and pathology of sex determination and differentiation. 2012;6(6):292-7.

Camats N, Fernández-Cancio M, Audí L, Schaller A, Flück CE. Broad phenotypes in
heterozygous NR5A1 46,XY patients with a disorder of sex development: an oligogenic origin?
European journal of human genetics : EJHG. 2018;26(9):1329-38.

410 24. Martínez de LaPiscina I, Mahmoud RA, Sauter KS, Esteva I, Alonso M, Costa I, et al. Variants
411 of STAR, AMH and ZFPM2/FOG2 May Contribute towards the Broad Phenotype Observed in 46,XY
412 DSD Patients with Heterozygous Variants of NR5A1. International journal of molecular sciences.
413 2020;21(22).

414 25. Mazen I, Abdel-Hamid M, Mekkawy M, Bignon-Topalovic J, Boudjenah R, El Gammal M, et al.
415 Identification of NR5A1 Mutations and Possible Digenic Inheritance in 46,XY Gonadal Dysgenesis.
416 Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and
417 pathology of cov determination and differentiation. 2016;10(2):147-51.

417 pathology of sex determination and differentiation. 2016;10(3):147-51.

41826.Werner R, Mönig I, Lünstedt R, Wünsch L, Thorns C, Reiz B, et al. New NR5A1 mutations and419phenotypic variations of gonadal dysgenesis. PloS one. 2017;12(5):e0176720.

420 27. Eggers S, Sadedin S, van den Bergen JA, Robevska G, Ohnesorg T, Hewitt J, et al. Disorders of
421 sex development: insights from targeted gene sequencing of a large international patient cohort.
422 Genome biology. 2016;17(1):243.

28. Robevska G, van den Bergen JA, Ohnesorg T, Eggers S, Hanna C, Hersmus R, et al. Functional
characterization of novel NR5A1 variants reveals multiple complex roles in disorders of sex
development. Hum Mutat. 2018;39(1):124-39.

426 29. Wang H, Zhang L, Wang N, Zhu H, Han B, Sun F, et al. Next-generation sequencing reveals
427 genetic landscape in 46, XY disorders of sexual development patients with variable phenotypes.
428 Human genetics. 2018;137(3):265-77.

429 30. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform.
430 Bioinformatics. 2010;26(5):589-95.

431 31. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al.
432 From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices

433 pipeline. Curr Protoc Bioinformatics. 2013;43(1110):11.0.1-.0.33.

434 32. Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and
435 wANNOVAR. Nat Protoc. 2015;10(10):1556-66.

436 33. Meynert AM, Ansari M, FitzPatrick DR, Taylor MS. Variant detection sensitivity and biases in
437 whole genome and exome sequencing. BMC Bioinformatics. 2014;15(1):247.

438 34. Arteche-López A, Ávila-Fernández A, Romero R, Riveiro-Álvarez R, López-Martínez MA,

439 Giménez-Pardo A, et al. Sanger sequencing is no longer always necessary based on a single-center

validation of 1109 NGS variants in 825 clinical exomes. Scientific reports. 2021;11(1):5697.

All rights reserved. No reuse allowed without permission.

441 35. De Cario R, Kura A, Suraci S, Magi A, Volta A, Marcucci R, et al. Sanger Validation of High-442 Throughput Sequencing in Genetic Diagnosis: Still the Best Practice? Frontiers in genetics. 443 2020;11:592588. 444 36. Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, et al. VarSome: 445 the human genomic variant search engine. Bioinformatics. 2019;35(11):1978-80. 446 37. Renaux A, Papadimitriou S, Versbraegen N, Nachtegael C, Boutry S, Nowé A, et al. ORVAL: a 447 novel platform for the prediction and exploration of disease-causing oligogenic variant 448 combinations. Nucleic Acids Res. 2019;47(W1):W93-w8. 449 38. Ewen KA, Olesen IA, Winge SB, Nielsen AR, Nielsen JE, Graem N, et al. Expression of FGFR3 450 during human testis development and in germ cell-derived tumours of young adults. Int J Dev Biol. 451 2013;57(2-4):141-51. 452 Pitetti JL, Calvel P, Zimmermann C, Conne B, Papaioannou MD, Aubry F, et al. An essential 39. 453 role for insulin and IGF1 receptors in regulating sertoli cell proliferation, testis size, and FSH action in 454 mice. Molecular endocrinology (Baltimore, Md). 2013;27(5):814-27. 455 40. Jacobi CL, Rudigier LJ, Scholz H, Kirschner KM. Transcriptional regulation by the Wilms tumor 456 protein, Wt1, suggests a role of the metalloproteinase Adamts16 in murine genitourinary 457 development. J Biol Chem. 2013;288(26):18811-24. 458 41. Barseghyan H, Symon A, Zadikyan M, Almalvez M, Segura EE, Eskin A, et al. Identification of 459 novel candidate genes for 46,XY disorders of sex development (DSD) using a C57BL/6J-Y (POS) mouse 460 model. Biol Sex Differ. 2018;9(1):8. 461 Globa E, Zelinska N, Shcherbak Y, Bignon-Topalovic J, Bashamboo A, McElreavey K. Disorders 42. 462 of Sex Development in a Large Ukrainian Cohort: Clinical Diversity and Genetic Findings. Frontiers in 463 endocrinology. 2022;13:810782. 464 Zidoune H, Ladjouze A, Chellat-Rezgoune D, Boukri A, Dib SA, Nouri N, et al. Novel Genomic 43. 465 Variants, Atypical Phenotypes and Evidence of a Digenic/Oligogenic Contribution to 466 Disorders/Differences of Sex Development in a Large North African Cohort. Frontiers in genetics. 467 2022;13:900574. 468 44. Li L, Gao F, Fan L, Su C, Liang X, Gong C. Disorders of Sex Development in Individuals 469 Harbouring MAMLD1 Variants: WES and Interactome Evidence of Oligogenic Inheritance. Frontiers in 470 endocrinology. 2020;11:582516. 471 Baxter RM, Arboleda VA, Lee H, Barseghyan H, Adam MP, Fechner PY, et al. Exome 45. 472 sequencing for the diagnosis of 46,XY disorders of sex development. The Journal of clinical 473 endocrinology and metabolism. 2015;100(2):E333-44. 474 46. Jameson SA, Lin YT, Capel B. Testis development requires the repression of Wnt4 by Fgf 475 signaling. Developmental biology. 2012;370(1):24-32. 476 Li Y, Zheng M, Lau YF. The sex-determining factors SRY and SOX9 regulate similar target 47. 477 genes and promote testis cord formation during testicular differentiation. Cell Rep. 2014;8(3):723-478 33. 479 48. Flück CE, Audí L, Fernández-Cancio M, Sauter KS, Martinez de LaPiscina I, Castaño L, et al. 480 Broad Phenotypes of Disorders/Differences of Sex Development in MAMLD1 Patients Through 481 Oligogenic Disease. Frontiers in genetics. 2019;10:746. 482 49. Kinuta K, Tanaka H, Moriwake T, Aya K, Kato S, Seino Y. Vitamin D is an important factor in 483 estrogen biosynthesis of both female and male gonads. Endocrinology. 2000;141(4):1317-24. 484 50. Djurovic J, Stamenkovic G, Todorovic J, Aleksic N, Stojkovic O. Polymorphisms and 485 haplotypes in VDR gene are associated with female idiopathic infertility. Hum Fertil (Camb). 486 2020;23(2):101-10. 487 51. Cariboni A, Hickok J, Rakic S, Andrews W, Maggi R, Tischkau S, et al. Neuropilins and their 488 ligands are important in the migration of gonadotropin-releasing hormone neurons. J Neurosci. 489 2007;27(9):2387-95. 490 52. Cariboni A, Davidson K, Rakic S, Maggi R, Parnavelas JG, Ruhrberg C. Defective gonadotropin-491 releasing hormone neuron migration in mice lacking SEMA3A signalling through NRP1 and NRP2:

perpetuity. All rights reserved. No reuse allowed without permission.

492 implications for the aetiology of hypogonadotropic hypogonadism. Human molecular genetics. 493 2011;20(2):336-44. 494 53. Qiao J, Han B. Diseases caused by mutations in luteinizing hormone/chorionic gonadotropin 495 receptor. Prog Mol Biol Transl Sci. 2019;161:69-89. 54. 496 McTaggart SJ, Algar E, Chow CW, Powell HR, Jones CL. Clinical spectrum of Denys-Drash and 497 Frasier syndrome. Pediatr Nephrol. 2001;16(4):335-9. 498 Dabrowski E, Armstrong AE, Leeth E, Johnson E, Cheng E, Gosiengfiao Y, et al. Proximal 55. 499 Hypospadias and a Novel WT1 Variant: When Should Genetic Testing Be Considered? Pediatrics. 500 2018;141(Suppl 5):S491-s5. 501 56. Wang Y, Li Q, Xu J, Liu Q, Wang W, Lin Y, et al. Mutation analysis of five candidate genes in 502 Chinese patients with hypospadias. European journal of human genetics : EJHG. 2004;12(9):706-12. 503 Bagchi D, Andrade J, Shupnik MA. A new role for wilms tumor protein 1: differential activities 57. 504 of + KTS and -KTS variants to regulate LH β transcription. PloS one. 2015;10(1):e0116825. 505 58. Bouma GJ, Hudson QJ, Washburn LL, Eicher EM. New Candidate Genes Identified for 506 Controlling Mouse Gonadal Sex Determination and the Early Stages of Granulosa and Sertoli Cell 507 Differentiation 1. Biology of Reproduction. 2010;82(2):380-9. 508 Beverdam A, Koopman P. Expression profiling of purified mouse gonadal somatic cells during 59. 509 the critical time window of sex determination reveals novel candidate genes for human sexual 510 dysgenesis syndromes. Human molecular genetics. 2006;15(3):417-31. 511 Guo MH, Plummer L, Chan YM, Hirschhorn JN, Lippincott MF. Burden Testing of Rare 60. 512 Variants Identified through Exome Sequencing via Publicly Available Control Data. Am J Hum Genet. 513 2018;103(4):522-34. 514 Eggers S, Sinclair A. Mammalian sex determination—insights from humans and mice. 61. 515 Chromosome research : an international journal on the molecular, supramolecular and evolutionary 516 aspects of chromosome biology. 2012;20(1):215-38. 517 Portnoi MF, Dumargne MC, Rojo S, Witchel SF, Duncan AJ, Eozenou C, et al. Mutations 62. 518 involving the SRY-related gene SOX8 are associated with a spectrum of human reproductive 519 anomalies. Human molecular genetics. 2018;27(7):1228-40. 520 63. Miller WL, Huang N, Pandey AV, Flück CE, Agrawal V. P450 oxidoreductase deficiency: a new 521 disorder of steroidogenesis. Ann N Y Acad Sci. 2005;1061:100-8. 522 Nie X, Arend LJ. Pkd1 is required for male reproductive tract development. Mech Dev. 64. 523 2013;130(11-12):567-76. Liu B, Chen SC, Yang YM, Yan K, Qian YQ, Zhang JY, et al. Identification of novel PKD1 and 524 65. 525 PKD2 mutations in a Chinese population with autosomal dominant polycystic kidney disease. 526 Scientific reports. 2015;5:17468. 527 Brown TR, Lubahn DB, Wilson EM, French FS, Migeon CJ, Corden JL. Functional 66. 528 characterization of naturally occurring mutant androgen receptors from subjects with complete 529 androgen insensitivity. Molecular endocrinology (Baltimore, Md). 1990;4(12):1759-72. 530 67. Camats N, Flück CE, Audí L. Oligogenic Origin of Differences of Sex Development in Humans. 531 International journal of molecular sciences. 2020;21(5). 532 Délot EC, Vilain E. Towards improved genetic diagnosis of human differences of sex 68. 533 development. Nature reviews Genetics. 2021;22(9):588-602. 534 Bouty A, Ayers KL, Pask A, Heloury Y, Sinclair AH. The Genetic and Environmental Factors 69. 535 Underlying Hypospadias. Sexual development : genetics, molecular biology, evolution, 536 endocrinology, embryology, and pathology of sex determination and differentiation. 2015;9(5):239-537 59. 538 70. Martinez de LaPiscina I, Flück CE. Genetics of human sexual development and related 539 disorders. Current opinion in pediatrics. 2021;33(6):556-63. 540 Martinez de LaPiscina I, de Mingo C, Riedl S, Rodriguez A, Pandey AV, Fernández-Cancio M, 71. 541 et al. GATA4 Variants in Individuals With a 46,XY Disorder of Sex Development (DSD) May or May

- 542 Not Be Associated With Cardiac Defects Depending on Second Hits in Other DSD Genes. Frontiers in 543 endocrinology. 2018;9:142.
- 544 72. Zhang W, Shi J, Zhang C, Jiang X, Wang J, Wang W, et al. Identification of gene variants in 130
- 545 Han Chinese patients with hypospadias by targeted next-generation sequencing. Molecular genetics 546 & genomic medicine. 2019;7(8):e827.
- 547 73. Kolesinska Z, Acierno J, Jr., Ahmed SF, Xu C, Kapczuk K, Skorczyk-Werner A, et al. Integrating
- clinical and genetic approaches in the diagnosis of 46,XY disorders of sex development. Endocrine 548 549 connections. 2018;7(12):1480-90.
- 550 74. 60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Hormone research in paediatrics. 2022;95(suppl 2)(2):1-616. 551
- 552 75. Gentilin B, Forzano F, Bedeschi MF, Rizzuti T, Faravelli F, Izzi C, et al. Phenotype of five cases
- of prenatally diagnosed campomelic dysplasia harboring novel mutations of the SOX9 gene. 553
- 554 Ultrasound Obstet Gynecol. 2010;36(3):315-23.

555

Table 1. Phenotype of the DSD patients harbouring the *NR5A1*/SF-1 p.Gly146Ala variant. Further details including biochemical data are given in Supplementary table 2.

Patient/ Origin ^a	Karyotype/Sex assignment ^b	Zygosity ^c	Age range at diagnosis	External genital phenotype ^d	Internal phenotype	Gonadal/reproductive function	Other organ anomalies
11	46,XY/M	Het	0-5y	Mild	Laparoscopy: absence of female organs and gonadal tissue. Histology: undifferentiated tissue.	0-5y, abnormal (no T response to hCG)	No
2 ²	46,XX/M	Het	6-10y	Opposite sex	US: no Müllerian ducts. Histology: infantile ovary with follicular cysts, fallopian tube, atrophic uterus, mesonefric remnant.	hCG test with hyperandrogenic reaction for typical male	No
3 ²	46,XY/M	Het	6-10y	Severe	US: inguinal testes (right 0.5cc; left 0.6cc).	6-10y, normal hCG test	No
4 ²	46,XX/M	Hom	6-10y	Opposite sex	Laparoscopy: bilateral gonads in inguinal canal and iliac area, atrophic uterus. No Müllerian ducts. Histology: bilateral ovotestes.	hCG test with hyperandrogenic reaction for typical male	No
5²	46,XX/M	Hom	0-5y	Opposite sex	US: inguinal bilateral gonads (1ml), no Müllerian ducts. Histology: ovarian tissue (left), testicular and ovarian tissue (right).	hCG test with hyperandrogenic reaction for typical male	No
6 ²	46,XY/M	Het	0-5y	Mild	MRI: absence of uterus and ovaries.	0-5y, normal baseline and hCG test	Anal agenesis, iron deficiency
7 ²	46,XY/M	Hom	6-10y	Severe	US: scrotal right testis (15x9mm), inguinal left testis (13x6mm).	6-10y, normal baseline and hCG test	No
8 ²	46,XY/F	Het	6-10y	Opposite sex	US: vaginal opening, no uterus. Histology: normal testis tissue at age ranges 6-10y and 21-25y.	31-35y, abnormal (high gonadotropins and low T)	No
9 ³	46,XY/M	Hom	6-10y	Typical	ND	6-10y, high T at baseline	Pituitary adenoma, hearing loss
10 ²	46,XX/M	Hom	0-5y	Opposite sex	US: prepubertal uterus. Histology: ovarian tissue (left), testicular and ovarian tissue (right).	Prepubertal	No
11 ¹	46,XY/M	Het	0-5y	Mild	US: normal size intrascrotal testes.	11-15y, normal (normal T and gonadotropins)	No
12 ³	46,XY/M	Het	0-5y	Severe	ND	ND	Left renal agenesis, lipomeningocele
13 ¹	46,XY/F	Het	11-15y	Opposite sex	Infantile uterus and ovaries by ultrasound.	ND	Abdominal obesity
14 ¹	46,XY/M	Het	0-5y	Severe	US: normal uterus, absence of gonads.	Abnormal (high gonadotropins and normal T)	No


F, female; hCG, human chorionic gonadotropin; M, male; MRI, magnetic resonance imaging; ND, not determined; T, testosterone; US, ultrasound; y, years. ^aOrigin of the patients: ¹Spanish; ²African;³Asian. ^bNone of the patients was sex re-assigned. ^cZygosity of the *NR5A1*/SF-1 p.Gly146Ala variant identified by targeted gene panel. ^dSeverity of the atypical phenotype of the external genitalia was classified according to (74).


Patient	Chromosome position	Gene (Name)	Variant	Туре	dbSNP	Zygosity	Previously reported ^a
	4:1807384	FGFR3 (Fibroblast Growth Factor Receptor 3)	c.1633_1634del;	frameshift deletion	ND	het	
1	5:5232601	ADAMTS16 (ADAM Metallopeptidase with Thrombospondin Type 1 Motif 16)	c.1822_1823del; p.His608*	stopgain	ND	het	
	19:7184641	INSR (Insulin Receptor)	c.660_661del; p.Pro220Hisfs*4	frameshift deletion	ND	het	
	2:120989442	GLI2 (GLI Family Zinc Finger 2)	c.3528G>T; p.Gln1176His	nonsynonymous SNV	rs139686081	het	
3	8:60743055	CHD7 (Chromodomain Helicase DNA Binding Protein 7)	c.1623C>A; p.His541Gln	nonsynonymous SNV	ND	het	
	11:77181567	MYO7A (Myosin VIIA)	c.2882G>A; p.Gly961Asp	nonsynonymous SNV	rs199575418	het	
	12:47865148	VDR (Vitamin D Receptor)	c.176C>T; p.Thr59lle	nonsynonymous SNV	rs145002466	het	
6	10:33330774	NRP1 (Neuropilin 1)	c.182C>A; p.Pro61Gln	nonsynonymous SNV	ND	het	
8	2:48698724	LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor)	c.757T>C; p.Ser253Pro	nonsynonymous SNV	ND	hom	
9	11:32428517	WT1 (WT1 Transcription Factor)	c.764T>A; p.Met255Lys	nonsynonymous SNV	rs377573993	het	
10	9:114275766	COL27A1 (Collagen Type XXVII Alpha 1 Chain)	c.3715C>T; p.Arg1239Trp	nonsynonymous SNV	rs143724625	het	
10	15:41564270	TYRO3 (TYRO3 Protein Tyrosine Kinase)	c.666_667insCACTGCCTGCAGCCC CCTTCAACATCACC; p.Ala223Hisfs*21	frameshift insertion	ND	het	
11	16:984721	SOX8 (SRY-Box Transcription Factor 8)	c.676A>C; p.Thr226Pro	nonsynonymous SNV	ND	het	
	7:75985941	POR (Cytochrome P450 Oxidoreductase)	c.1679C>T; p.Thr560Met	nonsynonymous SNV	rs574694698	het	
12	16:2114399	<i>PKD1</i> (Polycystin 1, Transient Receptor Potential Channel Interacting)	c.2624C>T; p.Pro875Leu	nonsynonymous SNV	ND	het	
12	16:30737182	SRCAP (Snf2 Related CREBBP Activator Protein)	c.7142G>A; p.Arg2381His	nonsynonymous SNV	rs765139685	het	
	17:72123563	SOX9 (SRY-Box Transcription Factor 9)	c.710dup; p.Pro238Thrfs*14	frameshift insertion	ND	het	Campomelic dysplasia (75)
13	X:67721837	AR (Androgen Receptor)	c.2323C>T; p.Arg775Cys	nonsynonymous SNV	rs137852562	hemi	AIS (66)
14	11:77194460	MYO7A (Myosin VIIA)	c.4259G>A; p.Arg1420His	nonsynonymous SNV	rs568337942	het	
	16:984739	SOX8 (SRY-Box Transcription Factor 8)	c.694A>C; p.Lys232Gln	nonsynonymous SNV	rs1596200787	het	


Table 2. Additional gene variants identified in the DSD patients harbouring the *NR5A1*/SF-1 p.Gly146Ala variant.

AIS, androgen insensitivity syndrome; Hemi, hemizygous; Het, heterozygous; Hom, homozygous; ND, not determined; POI, primary ovarian insufficiency. Variants classified as pathogenic, likely pathogenic or as of unknown significance according to the ACMG (American College of Medical Genetics) are highlighted in bold. ^aPreviously associated disease to the specific variant identified in this work.

Figure 1. Algorithm of genetic workup. A. Mode of genetic analysis, e.g. panel and whole exome sequencing (WES). Three patients were identified with pathogenic variants in LHCGR, WT1 and AR by panel analysis and were not further analyzed by whole-exome sequencing (WES). B. Filtering algorithm of genetic data. Steps used for variant filtering after WES of eleven DSD patients harboring the NR5A1/SF-1 p.Gly146Ala variant are depicted (letters a to f). Final candidates and their possible impact are listed and characterized in Table 2 and Supplementary Table 3.







All rights reserved. No reuse allowed without permission.

Figure 3. Genetic variants identified in 14 DSD patients harboring the NR5A1/SF-1 p.Gly146Ala variant illustrated with respect to the known pathways of male and female sex determination and differentiation. The scheme shows an overview of involved genes and their currently assumed relationship to sexual development. Genes with variants identified by whole exome sequencing in the patients have specific colors. In dark blue: candidate genes in patient 1; in brown: candidate genes in patient 3; in green: candidate genes in patient 6; in yellow: candidate genes in patient 8; in dark red: candidate genes in patient 9; in red: candidate genes in patient 10; in pink: candidate genes in patient 11; in light blue: candidate genes in patient 12; in purple: candidate genes in patient 13; in orange: candidate genes in patient 14; in dark grey: known genes involved in sexual development. Interrogation mark (?): function/timing/location is not clear; arrows: activation; inhibitors: inhibition; lines: interaction/partnership; dashed lines/arrows: hormone production.

